Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain DXCM message board posts where the ticker symbol DXCM has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest DXCM SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001093557-18-000169 Size: 7 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001093557-18-000167 Size: 12 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001093557-18-000165 Size: 11 KB
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000902219-18-000489 (34 Act)  Size: 33 KB
2018-08-10 005-81357
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001093557-18-000163 Size: 8 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-035463 Size: 3 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001093557-18-000161 Size: 5 KB
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001093557-18-000159 (34 Act)  Size: 5 MB
2018-08-01 000-51222
8-K  Documents Current report, items 5.02 and 9.01
Acc-no: 0001193125-18-234971 (34 Act)  Size: 24 KB
2018-08-01 000-51222
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001093557-18-000158 (34 Act)  Size: 262 KB
2018-08-01 000-51222
More DXCM SEC Filings

Related news from
Tue, 14 Aug 2018
05:40:13 +0000
Edited Transcript of DXCM earnings conference call or presentation 1-Aug-18 8:30pm GMT
Q2 2018 DexCom Inc Earnings Call
Sat, 11 Aug 2018
11:00:00 +0000
Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring
Diabetes treatment has evolved since Mary Fortune was diagnosed in 1967 and hospitalized because there was no reliable way monitor her blood sugar. Fortune and other diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics.
Thu, 09 Aug 2018
13:01:21 +0000
What Does Tandem Diabetes Care’s Valuation Trend Indicate?
From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.
Sat, 04 Aug 2018
12:31:00 +0000
3 Stocks That Soared 20% or More This Week -- Which Are Still Buys?
Can the sizzling momentum continue for these hot stocks?
Fri, 03 Aug 2018
13:50:01 +0000
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
Fri, 03 Aug 2018
12:07:25 +0000
Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results
The company released its second-quarter financial results on July 30, and the next day, the stock rose 10.95% to $27.56 from its prior day’s close of $24.84. In the second quarter of 2018, Tandem Diabetes Care’s net revenues grew 60% to $34.1 million compared to $21.3 million in the second quarter of 2017. Tandem Diabetes Care anticipates net revenues in fiscal 2018 to be $140 million–$148 million, which reflects 30%–38% year-over-year growth.
Fri, 03 Aug 2018
12:00:00 +0000
Today’s Research Reports on Stocks to Watch: DexCom and Exact Sciences
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / DexCom and Exact Sciences Corporation went in separate directions after reporting second quarter results. DexCom exploded and hit a new high after reporting an earnings beat while Exact Sciences slipped almost 13% after missing its revenue expectations. DexCom, Inc. shares closed up 30.65% on nearly 7 million shares traded.
Thu, 02 Aug 2018
18:18:25 +0000
DexCom Stock Skyrockets on Q2 Earnings Beat
DexCom’s positive earnings report for the second quarter of the year begins with losses per share of 10 cents. It was also great news for DXCM stock by beating out Wall Street’s losses per share estimate of 18 cents for the period. During the second quarter of the year, DexCom reported net income of $30.20 million.
Thu, 02 Aug 2018
18:06:00 +0000
Dexcom stock surges 30% on better-than-expected revenue results
DexCom Inc. (DXCM) shares surged nearly 30% in extremely heavy Thursday trade after the company reported a second-quarter revenue beat and narrower-than-expected loss. The company said it had an adjusted loss per share of 10 cents, excluding 48 cents per share in income from an investment in Tandem Diabetes Care as well as interest expense on senior convertible notes. The performance was "particularly notable" because the company's G6 platform -- a new iteration of the device that integrates with a smartphone, has a sensor that lasts 10 days and doesn't require a fingerstick test to measure blood sugar levels -- was only launched late in the quarter, Chief Executive Kevin Sayer noted.
Thu, 02 Aug 2018
15:59:00 +0000
Why Dexcom Is Soaring Today
Traders cheer after the company reports impressive second-quarter results. Here's what investors need to know.
Thu, 02 Aug 2018
12:54:11 +0000
The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...
Thu, 02 Aug 2018
12:45:00 +0000
What DexCom Just Said About Its Future
Sales momentum for the maker of continuous monitors for diabetes patients could accelerate.
Thu, 02 Aug 2018
12:44:21 +0000
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Cigna Corporation (NYSE: CI ) stock gained nearly ...
Wed, 01 Aug 2018
22:30:10 +0000
DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates
DexCom (DXCM) delivered earnings and revenue surprises of 50.00% and 18.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Wed, 01 Aug 2018
21:21:37 +0000
DexCom: 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had net income of 34 cents. Losses, adjusted for investment gains, came to 10 cents per share. The results topped Wall Street expectations. The ...
Wed, 01 Aug 2018
20:10:00 +0000
DexCom Executive Chairman and Director Terry Gregg Retires
DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that Terry Gregg has retired as the Company’s Executive Chairman and from the Company’s Board of Directors after 13 years with Dexcom. Kevin Sayer has been appointed Chairman of the Board, in addition to his current duties as President and CEO.
Wed, 01 Aug 2018
20:01:00 +0000
DexCom Reports Second Quarter 2018 Financial Results
DexCom, Inc. today reported its unaudited financial results as of and for the quarter ended June 30, 2018.
Wed, 01 Aug 2018
18:48:28 +0000
5 Connected Devices Stocks for a High-Tech Portfolio
The market for connected devices has been around for a lot longer than most people think. According to a report from LM Ericsson (NASDAQ:ERIC), the number of connected devices is forecast to hit 29 billion by 2022. While there are many benefits to connected devices, there are also some downsides.
Tue, 31 Jul 2018
14:30:35 +0000
How the Freestyle Libre CGM Opportunity Is Playing Out for ABT
Abbott Laboratories’ (ABT) Diabetes segment registered second-quarter sales growth of ~40.0%, reaching $470.0 million. The Diabetes segment’s strong performance was driven by the continued uptake of Abbott’s Freestyle Libre CGM (continuous glucose monitoring) device. The device was approved by the FDA in September 2017. Abbott Laboratories gained market share in the second quarter in the diabetes market space from competitors such as Medtronic (MDT) and Dexcom (DXCM) due to the strong momentum in its Freestyle Libre adoption.
Tue, 31 Jul 2018
12:04:17 +0000
See what the IHS Markit Score report has to say about Dexcom Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I have been a VF subscriber for one year and have found the members here generally to be informed, intelligent, articulate people of good will. The knowledge I've gathered has been well worth the price of tuition, and the subscription fee has been repaid many-fold in investment gains." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards